Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018
Abstract Background Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. Methods Eleven thousand four hundred...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-10-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-019-1199-3 |
id |
doaj-491f4f2adc064f24a1776a338e944e10 |
---|---|
record_format |
Article |
spelling |
doaj-491f4f2adc064f24a1776a338e944e102020-11-25T03:58:59ZengBMCRespiratory Research1465-993X2019-10-0120111210.1186/s12931-019-1199-3Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018Wan-mei Song0Yi-fan Li1Xiao-bin Ma2Jin-yue Liu3Ning-ning Tao4Yao Liu5Qian-yun Zhang6Ting-ting Xu7Shi-jin Li8Chun-Bao Yu9Lei Gao10Liang-liang Cui11Huai-chen Li12Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversitySchool of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical SciencesPeking Union Medical CollegeDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Chest HospitalNHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Biostatistics, School of Public Health, Shandong UniversityDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong UniversityAbstract Background Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. Methods Eleven thousand four hundred sixty-seven newly diagnosed and 1981 retreated TB cases with drug susceptibility data were included. Chi-Square test for trends, linear regression, a joinpoint regression model and temporal trend in proportions of the different resistance patterns were carried out. Results The proportion of primary DR-TB and mono-resistant TB (MR-TB) in China had reduced by more than 12% since 2004, and were 21.38%, 13.35% in 2018 respectively. Among primary DR-TB cases (2173,18.95%), the percentage of multiresistant TB (MDR-TB, from 5.41 to 17.46%), male (from 77.03 to 84.13%), cavity (from 13.51 to 43.92%), rifampicin(RFP)-resistant TB (from 8.11 to 26.98%), streptomycin(SM)-resistant TB (from 50.00 to 71.43%) increased significantly (P < 0.05). On the contrary, the proportion of female, non-cavity, isoniazide(INH)-resistant TB (from 55.41 to 48.15%) and MR-TB (from 82.43 to 62.43%) decreased significant (P < 0.05). The primary drug resistance rate among female, cavity, smoking, drinking, 15 to 44 year-old TB subgroups increased by 0.16, 6.24, 20.95, 158.85, 31.49%, respectively. The percentage of primary DR-TB, RFP-resistant TB dropped significantly during 2004–2007 in Joinpoint regression model. Conclusion The total rate of drug resistance among new TB cases showed a downward trend in Shandong, China, from 2004 to 2018. Primary drug resistance patterns were shifting from female, non-cavity, INH-resistant TB, and MR-TB groups to male, cavity, RFP/SM-resistant TB, and MDR-TB groups. Considering the rising drug resistance rate among some special population, future control of primary DR-TB in China may require an increased focus on female, cavity, smoking, drinking, or 15 to 44 year-old TB subgroups.http://link.springer.com/article/10.1186/s12931-019-1199-3TuberculosisPrimary drug resistanceEpidemiologyRisk factorsJoinpoint regression model |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wan-mei Song Yi-fan Li Xiao-bin Ma Jin-yue Liu Ning-ning Tao Yao Liu Qian-yun Zhang Ting-ting Xu Shi-jin Li Chun-Bao Yu Lei Gao Liang-liang Cui Huai-chen Li |
spellingShingle |
Wan-mei Song Yi-fan Li Xiao-bin Ma Jin-yue Liu Ning-ning Tao Yao Liu Qian-yun Zhang Ting-ting Xu Shi-jin Li Chun-Bao Yu Lei Gao Liang-liang Cui Huai-chen Li Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 Respiratory Research Tuberculosis Primary drug resistance Epidemiology Risk factors Joinpoint regression model |
author_facet |
Wan-mei Song Yi-fan Li Xiao-bin Ma Jin-yue Liu Ning-ning Tao Yao Liu Qian-yun Zhang Ting-ting Xu Shi-jin Li Chun-Bao Yu Lei Gao Liang-liang Cui Huai-chen Li |
author_sort |
Wan-mei Song |
title |
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_short |
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_full |
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_fullStr |
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_full_unstemmed |
Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018 |
title_sort |
primary drug resistance of mycobacterium tuberculosis in shandong, china, 2004–2018 |
publisher |
BMC |
series |
Respiratory Research |
issn |
1465-993X |
publishDate |
2019-10-01 |
description |
Abstract Background Primary drug-resistant tuberculosis (DR-TB) has contributed to a significant health and economic burden on a global scale, especially in China. we sought to estimate epidemiological characteristics of primary DR-TB in China from 2004 to 2018. Methods Eleven thousand four hundred sixty-seven newly diagnosed and 1981 retreated TB cases with drug susceptibility data were included. Chi-Square test for trends, linear regression, a joinpoint regression model and temporal trend in proportions of the different resistance patterns were carried out. Results The proportion of primary DR-TB and mono-resistant TB (MR-TB) in China had reduced by more than 12% since 2004, and were 21.38%, 13.35% in 2018 respectively. Among primary DR-TB cases (2173,18.95%), the percentage of multiresistant TB (MDR-TB, from 5.41 to 17.46%), male (from 77.03 to 84.13%), cavity (from 13.51 to 43.92%), rifampicin(RFP)-resistant TB (from 8.11 to 26.98%), streptomycin(SM)-resistant TB (from 50.00 to 71.43%) increased significantly (P < 0.05). On the contrary, the proportion of female, non-cavity, isoniazide(INH)-resistant TB (from 55.41 to 48.15%) and MR-TB (from 82.43 to 62.43%) decreased significant (P < 0.05). The primary drug resistance rate among female, cavity, smoking, drinking, 15 to 44 year-old TB subgroups increased by 0.16, 6.24, 20.95, 158.85, 31.49%, respectively. The percentage of primary DR-TB, RFP-resistant TB dropped significantly during 2004–2007 in Joinpoint regression model. Conclusion The total rate of drug resistance among new TB cases showed a downward trend in Shandong, China, from 2004 to 2018. Primary drug resistance patterns were shifting from female, non-cavity, INH-resistant TB, and MR-TB groups to male, cavity, RFP/SM-resistant TB, and MDR-TB groups. Considering the rising drug resistance rate among some special population, future control of primary DR-TB in China may require an increased focus on female, cavity, smoking, drinking, or 15 to 44 year-old TB subgroups. |
topic |
Tuberculosis Primary drug resistance Epidemiology Risk factors Joinpoint regression model |
url |
http://link.springer.com/article/10.1186/s12931-019-1199-3 |
work_keys_str_mv |
AT wanmeisong primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT yifanli primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT xiaobinma primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT jinyueliu primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT ningningtao primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT yaoliu primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT qianyunzhang primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT tingtingxu primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT shijinli primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT chunbaoyu primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT leigao primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT liangliangcui primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 AT huaichenli primarydrugresistanceofmycobacteriumtuberculosisinshandongchina20042018 |
_version_ |
1724456144460578816 |